Analyzing bacteria to predict antibiotic resistance in cystic fibrosis patients during lung infections
Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations
National Jewish Health · NCT04341532
This study is testing if analyzing bacteria in lung samples from cystic fibrosis patients during hospital stays can help predict antibiotic resistance and improve their treatment for lung infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Jewish Health (other) |
| Locations | 1 site (Denver, Colorado) |
| Trial ID | NCT04341532 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with cystic fibrosis (CF) who are hospitalized for treatment of pulmonary exacerbations (PEx). It aims to analyze sputum samples collected within 48 hours of hospital admission to identify markers of antimicrobial-resistant bacteria. By understanding the relationship between these markers and treatment responses, the study seeks to improve management strategies for PEx in CF patients. The research is conducted at National Jewish Health, in collaboration with the Cystic Fibrosis Foundation.
Who should consider this trial
Good fit: Ideal candidates are CF patients aged 18 and older who are hospitalized for intravenous treatment of an acute pulmonary exacerbation and are chronically infected with specific bacteria.
Not a fit: Patients who are not colonized with Pseudomonas aeruginosa and/or Staphylococcus aureus may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment strategies for cystic fibrosis patients experiencing pulmonary exacerbations.
How similar studies have performed: Other studies have shown promise in using bacterial profiling to inform treatment decisions, suggesting this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * CF patients 18 years or older who are hospitalized for IV treatment of an acute PEx * Chronically infected with Pseudomonas aeruginosa and/or Staphylococcus aureus * Can produce sputum * Can provide written consent * Willing to comply with study procedure Exclusion Criteria: * Subjects who are not colonized with Pseudomonas aeruginosa and/or Staphylococcus aureus * The presence of a condition or abnormality that, in the opinion of the Principal Investigator, would compromise the safety of the patient or the quality of the data
Where this trial is running
Denver, Colorado
- National Jewish Health — Denver, Colorado, United States (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cystic Fibrosis